Singapore markets closed

GlaxoSmithKline plc (GSK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
39.26-0.21 (-0.53%)
At close: 3:59PM EDT

39.26 0.00 (0.00%)
After hours: 4:00PM EDT

Full screen
Trade prices are not sourced from all markets
Previous close39.47
Open39.78
Bid39.31 x 900
Ask39.32 x 1200
Day's range39.18 - 39.80
52-week range31.43 - 48.25
Volume3,605,736
Avg. volume2,763,853
Market cap98.154B
Beta (5Y monthly)0.36
PE ratio (TTM)39.58
EPS (TTM)0.99
Earnings date01 Feb 2017 - 06 Feb 2017
Forward dividend & yield1.89 (4.79%)
Ex-dividend date14 May 2020
1y target est48.67
  • EU pays $384 million for Sanofi-GSK COVID vaccine as WHO scheme deadline looms
    Reuters

    EU pays $384 million for Sanofi-GSK COVID vaccine as WHO scheme deadline looms

    The European Union has agreed to buy a potential COVID-19 vaccine from Sanofi <SASY.PA> and GSK <GSK.L> in its second such deal to secure supplies, as a deadline for joining the World Health Organization's (WHO) vaccine purchase programme looms. In return for the right to the doses, the European Commission will finance part of the upfront costs faced by vaccine producers. The vaccine doses themselves will be bought by EU countries.

  • The Zacks Analyst Blog Highlights: Walmart, Oracle, Sanofi, Amazon, GlaxoSmithKline and CVS Health
    Zacks

    The Zacks Analyst Blog Highlights: Walmart, Oracle, Sanofi, Amazon, GlaxoSmithKline and CVS Health

    The Zacks Analyst Blog Highlights: Walmart, Oracle, Sanofi, Amazon, GlaxoSmithKline and CVS Health

  • 2 COVID-19 Antibody Stocks to Buy Right Now
    Motley Fool

    2 COVID-19 Antibody Stocks to Buy Right Now

    Luckily, there are over 300 coronavirus treatment candidates currently in various stages of preclinical and clinical studies. If successful antibody therapeutics could be developed to treat and prevent SARS-CoV-2 infections, they could be game-changers in the fight against the disease that's caused worldwide economic shutdowns and killed almost 200,000 people in the U.S. alone. GlaxoSmithKline (NYSE: GSK) and Regeneron (NASDAQ: REGN) are two companies leading the way in developing prospective antibody treatments for COVID-19.